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ABSTRACT
 
The ability to produce high quality instruments for the
assessment of quality of life has advanced considerably
in recent years. As the science progresses it has become
clear that certain standards must be met if outcome
measures are to be capable of providing useful, relia-
ble, and valid information within the context of clini-
cal studies and trials. This paper speciﬁes what these
standards are with particular reference to theoretical
basis, practicality, acceptability to respondents, unidi-
mensionality, scaling and psychometric properties, and
cultural validity and equivalence. The paper also indi-
cates how failure to achieve such standards results in
measures that are inaccurate and insensitive to true
changes in outcome.
Keywords: construct validity, cultural equivalence, dual
panel translation, quality of life.
 
Introduction
 
“All this he knows but will not tell
To those who cannot question well”
Percy Bysshe Shelley [1]
There are a number of requirements that any
instrument intended to collect information from
patients should meet. As the importance of a
number of these has only recently been recognized,
it is unlikely that many existing measures will meet
them all. Although failure on some of the require-
ments may not be serious enough to preclude their
use in a clinical trial, it may affect the way data are
analyzed and limit inferences that can be drawn
from these analyses.
 
Instrument Development
 
Theoretical Basis
 
All instruments should be based on a stated model
or theory of the construct being measured; a
requirement usually neglected in the development
of patient-reported outcome (PRO) measures.
There is a tendency for investigators to refer to any
PRO measure as a quality of life (QoL) instrument,
even where it was designed for a different purpose.
In their critical appraisal of the quality of QoL
measures, Gill and Feinstein [2] found that investi-
gators had deﬁned QoL conceptually in only 15%
of 75 articles they reviewed. This raises two related
problems. First, unless investigators explicitly state
what they mean by QoL it is not possible to deter-
mine whether their deﬁnition is reasonable. Sec-
ond, without such information it is not possible to
establish that an instrument has construct validity
[3].
 
Content Derivation
 
It is now generally agreed that the content of any
QoL measure must be derived directly from relevant
respondents [4,5]. This applies both to the issues
covered by the instrument and (as far as possible) to
the actual wording of its items. By deriving the
items from relevant individuals it is possible to
ensure that appropriate QoL concerns are included
[6,7]. Measures consisting of questions written by
the authors or drawn from the literature reﬂect pro-
fessional views of the experience of disease, rather
than those of potential respondents.
The content of an instrument should also be
appropriate to the culture and lifestyle of the coun-
tries in which it will be used. Instruments developed
in a single country reﬂect the language and culture
of that particular society, resulting in problems
when adapting the measure into other languages.
Deriving the content from patient interviews con-
ducted in different countries maximizes the cultural
relevance of the measure [8].
 Doward et al.
 
S14
 
Acceptability to Respondents
 
The respondents should perceive the content of a
measure as relevant. One of the major disadvan-
tages of the generic health status instruments is that,
by deﬁnition, they will include some items that are
inappropriate for the speciﬁc health problem and
miss some areas of importance. By deriving the con-
tent of the instrument from relevant sources, prob-
lems of nonapplicability are avoided and face and
content validity maximized.
 
Psychometric Properties
 
Unidimensionality
 
Any scale must be unidimensional if it is to provide
valid change scores. This applies to both single-scale
instruments and to individual scales within multi-
dimensional instruments. Until recently, test-
developers have relied on internal consistency
coefﬁcients to indicate unidimensionality but this
statistic merely indicates the degree of interrelation
between the items in a scale [9]. Different scales can
be added together and still have relatively high
internal consistency [3]. Factor-analytic methods
have also been used to assess the dimensional struc-
ture of scales. However, these are parametric meth-
ods requiring interval level data and so their use
may not always be scientiﬁcally valid. In addition, it
has been known for some time that factor analysis,
particularly with dichotomous data, produces spu-
rious factors [10]. Rasch analysis is now considered
to be the most efﬁcient means of establishing unidi-
mensionality [11]. However, such analyses have not
been applied to most existing patient-completed
outcome measures. Where such analyses have been
applied, the results tend to have been reported in
inadequate detail [12,13].
 
Reliability (Reproducibility)
 
Another essential quality of scales is that they
should have good reliability (that is, low random
measurement error). The appropriate method of
determining the reliability of an instrument
intended for use in a clinical trial is to apply it twice
to the same population and correlate the scores, as
stability over time (or reproducibility) is the crucial
variable. Where reliability is low; that is, where the
correlation coefﬁcient is below 0.85 [14] an instru-
ment will be unlikely to show changes in a patient’s
QoL.
 
Internal Consistency
 
Internal consistency is usually assessed through
Cronbach’s alpha coefﬁcients and informs on the
degree of interrelatedness of items. This property,
although not essential in itself, is a prerequisite for
unidimensionality. Items have to be interrelated if
they are to measure the same underlying construct.
At the same time Streiner and Norman [3] warn
against scales with very high alpha coefﬁcients, as
this indicates item redundancy.
 
Face and Content Validity
 
Potential  respondents  should  perceive  the  content
of any instrument as relevant. Too often test-
developers check the content of measures with clin-
ical experts only, neglecting the views of patients.
Patient interviews are required covering the suita-
bility and completeness of the content of the ques-
tionnaire and whether it is easy to understand and
complete [6,8].
 
Construct Validity
 
It  is  essential  to  establish  that  a  new  instrument
has construct validity, that is, that it is measuring
the intended construct. Three prerequisites of this
are that the instrument is based on a coherent the-
ory or deﬁnition [3], that the scale is unidimensional
[15], and that it has good reproducibility [3]. Where
these criteria are met it is possible to infer that the
instrument provides a valid assessment of the con-
struct deﬁned in the model. However, it is still
necessary to assess construct validity formally.
Assessing the construct validity of a health outcome
measure requires the speciﬁcation of hypotheses
and testing of relationships among clinical and
other PRO variables. There are many ways to do
this, the most common being through association
with instruments measuring related constructs (con-
vergent validity) and unrelated constructs (diver-
gent validity). The instrument employed as the
comparator measure should itself be of proven reli-
ability and validity. Thus, interscale correlations,
essentially using a new instrument to validate itself,
are not an adequate assessment of validity. Another
valuable approach is known groups’ validity. This
approach includes distinguishing the status of
patients at different stages of their disease or with
different disease severity. If hypotheses are con-
ﬁrmed with observed data, then there is evidence-
supporting validity. It is the accumulation of this
evidence that provides greater conﬁdence in the
validity of a measure.
 
Responsiveness
 
Any instrument intended for use in clinical trials or
for monitoring individual patient care should be
responsive, that is, able to detect real changes in the
 Requirements for QoL Instruments in Clinical Research
 
S15
 
measured construct. Measures with poor reproduc-
ibility have poor responsiveness, as in the case of
generic health status measures, such as the Notting-
ham Health Proﬁle and the SF-36 [16–19]. The abil-
ity of an instrument to detect changes within a
single group over time is necessary but not sufﬁcient
to indicate responsiveness. In order for an instru-
ment to have satisfactory responsiveness, it is also
necessary for it to have an adequate range of cov-
erage of the construct. For example, it should be
able to assess minor QoL impairment where the
instrument is intended for use in preventive studies
or where asymptomatic patients are included in the
trials.
 
Practicality for Use in Clinical Trial
 
Instruments should be practical if they are to be
included  in  clinical  trials.  They  should  be  short
and easy to answer and administer. Thus, complex
response systems should be avoided, as should the
requirement for trained administrators. In the latter
case, this increases resource consumption and may
reduce the willingness of respondents to acknowl-
edge problems [20]. The optimal mode of adminis-
tration for instruments included in a clinical trial is
self-administration. Here, resource input is minimal
and the likelihood that respondents will acknowl-
edge problems is maximized. Where an instrument
is well developed and tested, potential problems of
missing data or misunderstanding will be mini-
mized. Where repeated measurements are needed
over a period of time the instruments should be
administered in the same way and under the same
conditions on each occasion.
 
Cultural Considerations
 
Language Availability
 
As most clinical trials are now international, instru-
ments should be available in a large number of
languages. However, problems can arise where
attempts are made to adapt an instrument devel-
oped in one language for use in others. Given that
the instrument is in a ﬁnished format, cultural dif-
ferences may be impossible to overcome [8]. All
new versions produced should be shown to have
equivalent psychometric properties to those of the
original language version. This requires proper val-
idation studies to establish face and content validity,
reproducibility, and construct validity. To a large
extent cultural problems can be avoided where
instruments are developed simultaneously in the
countries for which they are required [21].
Given the expense of, and time required for
adapting instruments for use in additional coun-
tries, careful consideration should be given to select-
ing the countries in which a trial will be run. Rather
than recruiting a few patients from each of a large
number of countries it is more efﬁcient to select
larger numbers of participants from fewer countries
where validated versions of the outcome measures
are already available.
 
Language Equivalence
 
A number of groups have developed several lan-
guage versions of instruments without adequate
consideration of issues of cultural equivalence (see
for example [22–25]). It is always possible to
translate a questionnaire into a new language but it
does not follow automatically that the different
versions are directly comparable. Where it is
intended to combine QoL data from different
countries, the requirements of the scaling proper-
ties of the instrument are increased. It is necessary
to establish that the items in the scale, or in the
individual subscales, have the same ordering, in
terms of amount of the measured construct repre-
sented, in each language version. This assumes that
there will be little or no cultural bias in the individ-
ual items [26].
 
Summary
 
While some of these requirements have developed
or become more speciﬁc over recent years, they have
formed the framework around which all needs-
based measures have been built. By setting high psy-
chometric standards it is possible to ensure that new
instruments have the quality to be effective outcome
measures in clinical practice and trials.
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